How Smarteeva Submits an MDR to the FDA in 3 Minutes via ESG NextGen API

How MDR reporting works under 21 CFR Part 803

The FDA's Medical Device Reporting regulation assigns reporting obligations to three groups: manufacturers, importers, and device user facilities. Each has different requirements, different forms, and different timelines.

Manufacturers carry the broadest obligation. They must report events involving death or serious injury within 30 calendar days of becoming aware. Events where the manufacturer must take remedial action to prevent an unreasonable risk of substantial harm require reporting within 5 business days. Malfunctions that could cause or contribute to death or serious injury if they were to recur also require reporting within 30 days.

The definition of "becomes aware" is critical and frequently misunderstood. Under Part 803.50, a manufacturer becomes aware when any employee of the manufacturer receives information that reasonably suggests a reportable event has occurred. This does not mean when the Regulatory team receives the complaint, or when someone decides it is reportable. It means when any person at the company, including sales representatives, customer service agents, or field engineers, first learns about the event. The regulatory clock starts at that moment.

FDA Form 3500A is the standard manufacturer reporting form. It contains over 50 fields organized across patient information, device identification, event description, manufacturer information, and initial reporter details. Each section draws data from a different source system within the manufacturer's infrastructure.

Why late and inaccurate MDR submissions carry real consequences

MDR compliance is not a theoretical requirement. The FDA actively monitors submission timelines and data quality, and the consequences of failure are documented and public.

Late submissions are visible in the MAUDE database. The FDA can calculate the gap between the manufacturer's date of awareness and the submission date for every report. Consistent late reporting patterns can trigger a warning letter, a 483 observation during inspection, or formal enforcement action. The FDA's CDRH compliance program specifically looks for systematic delays in adverse event reporting as an indicator of quality system deficiencies.

Incomplete reports are rejected or flagged for follow-up. The most commonly missing fields across the industry are device product code, event type classification, and initial reporter information. Each rejection adds days to a process that is already running against a deadline, and the back-and-forth with the FDA generates additional documentation burden.

Inconsistent data between the complaint record and the MDR creates a different kind of risk. When an FDA inspector compares the complaint file to the MDR submission during an inspection and finds that the event description, product identifier, or IMDRF codes do not match, it raises questions about the manufacturer's quality system that can take weeks to resolve. One Smarteeva customer discovered a 9% mismatch rate between complaint-level IMDRF codes and MDR-level codes before implementation. That means roughly 1 in 11 regulatory submissions had a data integrity discrepancy.

From a patient safety perspective, accurate and timely MDR submissions feed the FDA's signal detection capabilities. When manufacturers submit incomplete or late reports, the FDA's ability to identify emerging safety patterns across the device population is diminished. MDR reporting is a compliance obligation and the data layer that regulators use to protect the public.

What the manual MDR process looks like at most manufacturers

The manual MDR process follows a predictable pattern at most mid-size and large medical device manufacturers.

A complaint enters the system and is eventually assessed as reportable. The Regulatory Affairs team is notified. An RA specialist opens the complaint record in the eQMS to review the event description and patient outcome. They then open the device master record in the ERP system to find the product code, model number, serial number, and manufacturing date. They open the CRM or customer database to find the reporter's contact information and the healthcare facility details.

With data from three or four systems assembled, the specialist begins populating FDA Form 3500A. They write the event description narrative from scratch, which requires synthesizing the complaint narrative, any investigation findings available at the time, and the IMDRF codes assigned during triage. This narrative typically takes 30 to 60 minutes to write because it must be factual, specific, and consistent with the underlying records.

The completed draft goes through internal review. A senior RA manager or Quality Director reviews the narrative, checks the field data against the complaint record, and approves for submission. This review step adds 1 to 3 business days depending on workload and availability.

Submission itself historically required the FDA's eSubmitter desktop application, which meant manually re-entering data that already existed in the manufacturer's systems into a separate tool. Even with newer submission methods, the data re-entry and narrative writing steps consume the majority of the 5 to 15 business days the process typically requires.

For manufacturers selling globally, the same complaint event may trigger reports in multiple jurisdictions: an FDA MDR in the US, a Manufacturer Incident Report under EU MDR Article 87, a Health Canada Mandatory Problem Report, and an MHRA Yellow Card in the UK. Each report has its own form, its own fields, its own timelines, and its own submission channel. The manual workload multiplies with every market.

How Smarteeva processes MDR submissions

• Automatic reportability assessment: When a complaint enters Smarteeva, country-driven decision trees evaluate the event type, severity, jurisdiction, and device classification in real time. The system does not wait for a human to decide whether the event is reportable. If the event meets the criteria under 21 CFR Part 803, the complaint is flagged immediately, and the regulatory routing begins. These decision trees are not a single set of US-only rules. They cover 80+ jurisdictions. A single complaint involving a serious injury may simultaneously trigger an FDA MDR (30-day or 5-day timeline), an EU MIR to the relevant competent authority (10-day or 15-day timeline depending on severity), a Health Canada CVR, and a BfArM notification. The system identifies all applicable reports from the same complaint event.

• Pre-populated form fields from connected data: Because complaint records, device master records, customer records, and reporter information all live in the same Salesforce environment, Smarteeva assembles the MDR from connected data without manual retrieval. The over 50 fields on FDA Form 3500A are populated from data that already exists. Fields that require manual input are highlighted. Nothing is auto-submitted without human review. The elimination of data retrieval from multiple systems is where the most time is saved. The 5 to 15 business days in the manual process are dominated by data gathering and assembly, not by the actual review and submission steps.

• AI-drafted narrative: The event description narrative is one of the most time-consuming fields in any MDR because it requires synthesizing information from the complaint, the investigation, and the device record into a factual, regulatory-appropriate account. Smarteeva generates a draft narrative from the complaint description, IMDRF codes, and any investigation findings recorded in the system. The Regulatory team reviews and edits this draft before submission. The AI does not write the final narrative. It provides a starting point that is already grounded in the source data, eliminating the blank-page problem that makes manual narrative writing slow.

• Direct submission via FDA ESG NextGen API: Smarteeva submits MDRs directly to the FDA through the Electronic Submissions Gateway NextGen API. The submission is validated against FDA field requirements before transmission. The system confirms receipt and logs the complete submission record in an audit trail that documents who submitted, when, what was included, and the FDA acknowledgement status. Average submission time from the moment a Regulatory team member clicks "Submit" to FDA receipt: 3 minutes. Follow-up and supplemental reports link back to the original submission. When the FDA requests additional information or the manufacturer identifies new findings during investigation, the supplemental report auto-populates fields from the original MDR. The team is not re-entering data that already exists.

‍

What 35% of FDA MDRs filed through one platform means for data integrity

35% of all Medical Device Reports submitted to the FDA are filed through Smarteeva. That number represents thousands of manufacturers across every device classification and company size, from single-product startups to global enterprises operating across 80+ countries.

The significance of this number extends beyond volume. When a substantial percentage of the FDA's MDR submissions pass through a single platform with standardized field extraction, bidirectional IMDRF code syncing, and automated validation checks, the overall data quality of the submissions improves. Consistent product codes, consistent event categorization, and consistent narrative structure make the data more useful for the FDA's own signal detection capabilities.

For individual manufacturers, the operational impact is measurable. One customer manages over 300,000 MDRs through the platform. The 3-minute submission time means that even on a Friday afternoon when a reportable event requires urgent filing, the 5-day clock is met without overtime, weekend work, or compressed review cycles.

The bidirectional IMDRF code sync between complaint records and MDR submissions eliminated the 9% mismatch rate at one customer site, reducing it to less than 0.001%. That level of data integrity means the complaint file and the regulatory submission tell the same story, every time, which is exactly what an FDA inspector expects to find during an audit.

Smarteeva's MDR automation is available as part of the platform's post-market surveillance suite. Teams already using Smarteeva for complaint management, PSURs, or recall management can activate MDR submission without a separate implementation. The same data model that drives complaint intake and investigation drives the regulatory report.

‍